This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for February 14th
by Zacks Equity Research
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
by Zacks Equity Research
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More
by Zacks Equity Research
Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector.
Galecto (GLTO) Down 71% as Lung Disease Candidate Fails
by Zacks Equity Research
Galecto's (GLTO) shares fall as the mid-stage study of GB0139 to treat idiopathic pulmonary fibrosis fails to meet its primary endpoint.
Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy
by Zacks Equity Research
Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health
by Zacks Equity Research
UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.
Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?
by Zacks Equity Research
Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.
Here's Why You Should Retain Community Health (CYH) Stock
by Zacks Equity Research
With contract labor headwinds likely to phase out as 2022 progresses, Community Health Systems' (CYH) margins are set to improve significantly.
Anthem (ANTM) Rises 3.7% Since Q4 Earnings, Reiterates View
by Zacks Equity Research
Anthem's (ANTM) Medicaid footprint is likely to grow on the back of the pending acquisition of Paramount Advantage's Ohio contracts, as service is expected to commence in July.
Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Galecto (GLTO) Enters Oversold Territory
by Zacks Equity Research
Galecto (GLTO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock